Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 20 vs AZASITE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy,Off-label: Treatment-resistant depression, obesity, cognitive enhancement
Treatment of bacterial conjunctivitis caused by susceptible organisms
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Primarily hepatic via CYP2D6 and, to a lesser extent, CYP2C19, CYP3A4, and CYP2C9. Metabolites include 4-hydroxyamphetamine, alpha-hydroxyamphetamine, and norephedrine.
Not significantly metabolized; primarily excreted unchanged in bile and urine.
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
16% (primarily albumin).
~50-60% bound to plasma proteins (primarily albumin).
3.2-5.6 L/kg; indicates extensive tissue distribution.
Vd: ~100 L/kg (extensive tissue penetration; not meaningful for topical use; systemic Vd based on IV data).
Oral IR: ~90%; ER: ~90%.
Ophthalmic: negligible systemic absorption (<10% of topical dose) due to low corneal permeability and dilution by tears.
e GFR 15-29 m L/min: 50% of usual dose. e GFR < 15 m L/min: avoid use due to accumulation risk. Hemodialysis: not recommended.
No dosage adjustment required for ophthalmic use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use.
No dosage adjustment required for ophthalmic use.
Children 3-5 years: 2.5 mg orally once daily; increase by 2.5 mg weekly. Children 6 years and older: 5 mg once or twice daily; increase by 5 mg weekly. Maximum dose: 40 mg/day (immediate-release). Weight-based: 0.3-1.5 mg/kg/day (immediate-release).
Safety and efficacy in pediatric patients have not been established; limited data available.
Initial: 2.5 mg once or twice daily; increase slowly by 2.5 mg increments at weekly intervals. Use lowest effective dose due to increased sensitivity and risk of cardiovascular adverse effects.
No specific dosage adjustment recommended; use same dosing as for adults.
Abuse and dependence: Amphetamines have a high potential for abuse, which can lead to dependence and serious cardiovascular events. Misuse may cause sudden death or serious cardiovascular adverse events.
None
Cardiovascular: Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities.,Psychiatric: Exacerbation of pre-existing psychosis, mania, or aggression; new-onset psychosis or mania.,Growth suppression: Long-term use in children may suppress growth.,Seizures: May lower seizure threshold in patients with seizure disorders.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Prolonged use may result in overgrowth of nonsusceptible organisms,Contact lens should not be worn during treatment,Do not inject subconjunctivally or introduce into the anterior chamber
Hypersensitivity to amphetamine or any component of the formulation,Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use or within 14 days of MAO inhibitors (risk of hypertensive crisis)
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,Hypersensitivity to any component of the formulation
High-fat meals can delay absorption of Adderall. Acidic foods (e.g., citrus fruits, juices) and vitamin C may decrease absorption; avoid within 1 hour of dosing. Caffeine and other stimulants may increase side effects. Alcohol should be avoided. Grapefruit juice may increase amphetamine levels, so limit or avoid.
No clinically significant food interactions. Administer with or without food as per dosing instructions.
First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of fetal growth restriction, preterm birth, neonatal withdrawal syndrome (irritability, poor feeding), and persistent pulmonary hypertension. Chronic use may impair fetal development.
Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observed in animal studies at doses up to 200 mg/kg/day (systemic). Limited human data; risk is considered low. First trimester: unlikely to cause major malformations. Second and third trimesters: no specific risks identified.
Excreted into breast milk; M/P ratio approximately 2.5–7.5. Relative infant dose estimated at 5–14% of maternal weight-adjusted dose. Potential for decreased appetite, insomnia, and growth suppression in breastfed infants. American Academy of Pediatrics recommends use only if benefit outweighs risk, with close monitoring.
Azithromycin is excreted into human milk after systemic administration; the M/P ratio is approximately 0.90. After ophthalmic administration, systemic absorption is minimal, resulting in negligible exposure to the infant. Considered compatible with breastfeeding; use with caution if eye drops are applied multiple times daily.
Due to increased renal clearance and expanded plasma volume, total amphetamine exposure may decrease, potentially requiring dose increase (monitor clinical response). However, insufficient data to recommend fixed adjustments; individualize based on symptom control and tolerability.
No dose adjustment is necessary for ophthalmic use in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) do not significantly affect topical ocular drug levels due to negligible systemic absorption.
Adderall 20 mg is a mixed amphetamine salt formulation (75% dextroamphetamine, 25% levoamphetamine). Monitor for cardiovascular adverse effects; consider baseline ECG in patients with cardiac risk factors. Avoid in patients with structural cardiac abnormalities, cardiomyopathy, or arrhythmias. Use with caution in patients with hypertension, hyperthyroidism, or glaucoma. May exacerbate tics and Tourette syndrome. Administer first dose upon awakening; avoid afternoon doses due to insomnia risk. Monitor growth in children; may cause weight loss and growth suppression. Assess for potential for abuse and dependence; use lowest effective dose.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic used for bacterial conjunctivitis. Shake well before each use. Avoid contact with contact lenses during treatment. Do not use for more than 14 days. Monitor for signs of hypersensitivity.
Take exactly as prescribed; do not crush or chew extended-release capsules.,Take early in the morning to avoid trouble sleeping.,Avoid taking with high-fat meals as it may delay absorption.,Do not drink alcohol while taking this medication.,Report any chest pain, shortness of breath, or fainting immediately.,Avoid driving or operating heavy machinery until you know how Adderall affects you.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.,Do not share your medication with others; it is a controlled substance.,Inform your doctor if you have a history of heart disease, high blood pressure, seizures, or mental health conditions.
Shake the bottle well before each use.,Wash hands before and after application.,Do not touch the dropper tip to any surface.,Remove contact lenses before use; do not reinsert during treatment.,Instill the prescribed number of drops in the affected eye(s).,Avoid wearing eye makeup during treatment.,Finish the entire course of medication even if symptoms improve.,Report any worsening, itching, or swelling to your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 20 vs AZASITE, answered by our medical review team.
ADDERALL 20 is a CNS Stimulant that works by Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.. AZASITE is a Macrolide Antibiotic that works by Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 20 and AZASITE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 20 is: Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).. The standard adult dose of AZASITE is: 1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 20 and AZASITE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 20 is classified as Category C. First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of f. AZASITE is classified as Category C. Azasite (azithromycin ophthalmic) is classified as FDA Pregnancy Category B. Systemic absorption is minimal after ophthalmic administration. No teratogenic effects have been observ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.